UK's RELX plans pay boost for CEO Engstrom, Sky News reports | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[AstraZeneca PLC]Follow[Relx PLC]Follow[Rolls-Royce Holdings PLC]FollowShow more companiesFeb 18 (Reuters) - British information group RELX [(REL.L), opens new tab] is preparing to grant its top boss, Erik Engstrom, a substantial pay rise, bringing it closer to its FTSE-100 peers like AstraZeneca [(AZN.L), opens n ...

As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.Here's the latest list of major overbought players in this sector.AstraZeneca plc (NYSE:AZN)Masimo Corp (NASDAQ:MASI)Geron Corp (NASDAQ:GERN)Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.Photo via Shutterstock ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

As I’ve covered in the past , I was bullish on NN Group ( NNGPF ) ( NNGRY ) since mid-2024 due to an interesting combination of a high-dividend yield and relatively cheap valuation. However, following aLabutes IR is a Fund Manager/Analyst specialized in the financial sector, with more than 18 years of experience in the financial markets. I have worked at several type of institutions in the industry, always at the buy side and related to portfolio management. Associated with the existing author The Outsider. ...

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced th ...

Economic Outlook - The Bank of England is urged to implement quick interest rate cuts to alleviate the cost-of-living crisis and boost consumer spending and business confidence [1][2] - Trade unions support interest rate cuts, citing easing inflation as beneficial for working families, with expectations of further softening due to government support for energy bills and other costs [2] - Firms are looking for inflation easing to be accompanied by measures to reduce business costs, such as business rates reform, to stimulate economic growth [3] Inflation and Interest Rates - The Consumer Price Index (CPI) has dropped to 3.0%, the lowest level in nearly a year, indicating potential for interest rate cuts by the Bank of England [25][28] - Analysts predict a 25 basis point cut in interest rates at the next Bank of England meeting, with further cuts anticipated if inflation continues to decline [19][21][20] - Despite the drop in headline inflation, services inflation remains sticky, suggesting caution from the Monetary Policy Committee [22] Market Performance - The FTSE 100 index has reached new record highs, driven by gains in sectors such as mining, defense, and banking [6][15][28] - BAE Systems has reported a 10% increase in sales to £30.7 billion and a record order book of £83.6 billion, reflecting strong demand in the defense sector [23][10] - Glencore's revenue for 2025 increased by 7% to $247.54 billion, with adjusted EBIT falling less than expected, indicating resilience in the mining sector [16][17] Company-Specific Developments - BAE Systems has increased its dividend by 10% and expects sales growth of 7-9% for the current year, supported by rising global defense spending [23][13] - Glencore's performance improved significantly in the second half of the year, aided by stronger metals prices and higher copper output [17] - BAE's free cash flow is projected to exceed £1.3 billion, contributing to a reduction in net debt by 22% [13][24]

European stocks closed mostly higher on Tuesday with the mood largely staying positive right through the day's session amid hopes of some monetary easing by a few central banks, including the Bank of England. Investors continued to follow geopolitical news and awaited fresh data from the U.S. for directional clues.Data showing an increase in UK's unemployment rate raised expectations of another rate cut by the Bank of England.The pan European Stoxx 600 gained 0.45%. The U.K.'s FTSE 100 climbed 0.79%, Germa ...

Wall Street’s major market averages ended near even on Friday as traders digested the latest round of key retail inflation data. The blue-chip Dow ended +0.1%. At the same time, the benchmark S&P 500 finished flat, and the tech-focused Nasdaq Composite fell by -0.2%. ...

Core Viewpoint - Shore Capital downgraded AstraZeneca from 'buy' to 'hold' due to a less favorable earnings trajectory as the company increases R&D spending to prioritize revenue growth [2] Group 1: Earnings and Revenue - AstraZeneca delivered 16 positive clinical readouts in 2025, expected to generate over $10 billion in peak year revenues [3] - A further 20 readouts anticipated in 2026 are expected to carry similar revenue potential [3] - Near-term earnings progression is projected to slow to a 10% compound annual growth rate between 2025 and 2028 due to surging R&D investment [3] Group 2: Valuation and Market Performance - The current valuation of AstraZeneca is considered full at 20 times forecast 2026 earnings, despite confidence in exceeding the $80 billion revenue target for 2030 [2] - AstraZeneca shares have increased by 11% year-to-date, trading at 15,068p, which is up 1% on the last trading day [4] - Shore Capital believes the premium valuation is justified by the company's diversified growth story and strong pipeline, but sees limited scope for further rating expansion due to the imbalance between revenue acceleration and earnings progression [4]

Key Takeaways TEM delivered 83% revenue growth in prelim 2025 results, with diagnostics and data segments surging. TEM recorded $1.1B TCV and positive adjusted EBITDA, but GAAP losses persisted. Tempus AI trades at 17.79X P/B, above industry average, raising valuation concerns. Tempus AI (TEM) is slated to release fourth-quarter 2025 results on Feb. 24, after market close. During the quarter, the company advanced several strategic collaborations and product innovations that are expected to further strengthe ...